ERBB2 and breast carcinoma: Gene amplification and overexpression of HER2 has been reported in for instance gastric- and endometrial cancers and urothelial bladder carcinoma [7], yet its clinical significance is perhaps best documented in breast cancer where these events have therapeutic implications [8].